Novel Viral Vectors for Gene Therapy
Synthetic Viral Vectors Show Promise for Mitigating Immune Response to Gene Therapy
Virus Supply Vexes Gene Therapy Developers, CMOs
Some Contract Manufacturing Organizations Are Ramping Up Capacity in Preparation for a Boom in Viral Vector Demand
Literature Review: Defending against Virus, with a Little Help from Microbiome
A Specific Human-Associated Gut Microbe Produced DAT and Rescued Antibiotic-Treated Influenza-Infected Mice
Genome-Wide Analysis of the Transcription Start Sites and Promoter Motifs of Phytoplasmas
RNA-Seq of Phytoplasmas Reveals Clues about Transcription Start Sites and Consensus Promoter Sequences
For full access to this article login to GEN Select now.
Quantifying Downstream Capacity Crunch
Column Resins Are Implicated by Many Experts As the Source of Biomanufacturing's Woes
- In today’s biomanufacturing environment, downstream capacity has become a partial roadblock to nearly all CMOs (94%) and more than half (61%) of biotherapeutic developers. Extensive data from 434 biopharmaceutical manufacturers in 32 countries is summarized in BioPlan Associates’ just-released 5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.